Physician profile
Surjeet Singh
NPI 1013114628
$8,408.09
in general payments reported to CMS, 2019-2025
26 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,159 · 2020: $1,465 · 2021: $1,886 · 2022: $1,352 · 2023: $1,117 · 2024: $961 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,546.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,458.77 | 2020-2025 | Idosetr, Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $1,185.88 | 2020-2025 | Clareon, Argos, Eysuvis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,036.56 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $754.58 | 2019-2023 | |
| Ivantis, INC | $692.75 | 2019-2021 | |
| Sight Sciences, INC. | $534.40 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $529.77 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| New World Medical,INC. | $444.00 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $324.63 | 2019-2022 | |
| Rxsight INC | $318.66 | 2021-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Eyepoint US, INC. | $183.87 | 2020-2021 | |
| Astellas Pharma US INC | $137.57 | 2024 | Izervay |
| Biotissue Holdings INC. | $135.49 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $132.02 | 2019 | |
| Allergan, INC. | $100.02 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $91.95 | 2023-2025 | Durysta |
| Mallinckrodt Hospital Products INC. | $63.08 | 2020-2024 | Acthar |
| Horizon Therapeutics Plc | $51.39 | 2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $45.29 | 2019 | |
| Oyster Point Pharma, INC. | $38.61 | 2022-2023 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $38.17 | 2020 | |
| Eyevance Pharmaceuticals LLC | $32.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $26.94 | 2019-2020 | |
| Amgen INC. | $25.02 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $13.71 | 2025 | Dextenza |
| Lensar, INC. | $12.35 | 2025 | Lensar Laser System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surjeet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.